Schizophrenia Research and Treatment / 2018 / Article / Tab 3

Research Article

Metabolic Syndrome among Schizophrenic Patients: A Comparative Cross-Sectional Study in the Middle Belt of Ghana

Table 3

MetS among studied subjects treated with atypical and typical antipsychotics.

VariablesTotalAtypicalTypical
n=159n=105n=54OR (95% CI)p-value

Met / NCEP/ATP III
012(7.5)6(5.7)6(11.1)1
165(41.3)41(39.1)24(44.5)1.7(0.5-5.9)0.522
258(36.2)40(38.1)18(33.3)2.2(0.6-7.8)0.316
≥324(15.0)18(17.1)6(11.1)3.0(0.6-12.9)0.157
Met / IDF
08(5.0)4(3.8)4(7.4)1
150(31.5)26(24.8)24(44.5)1.1(0.1-9.0)1.000
256(35.2)44(41.9)12(22.2)3.7(0.8-16.9)0.099
≥345(28.3)31(29.5)14(25.9)2.2(0.5-10.2)0.421
Met / WHO
012(7.6)6(5.7)6(11.1)1
153(33.3)34(32.0)19(35.2)1.8(0.5-6.3)0.512
255(34.6)36(34.0)19(35.2)1.9(0.5-6.7)0.341
≥339(24.5)29(44.3)10(18.5)2.9(0.8-11.1)0.157

NCEP ATP III: National Cholesterol Education Program, Adult Treatment Panel III; IDF: International Diabetes Federation; WHO: World Health Organization; MetS: metabolic syndrome; OR: odds ratio; CI: confidence interval; p<0.05 is statistically significant.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.